BGNE - BeiGene - Stock Price & Dividends

BeiGene Ltd is a biotech company focused on developing innovative treatments for cancer patients worldwide. Its portfolio includes commercial-stage products such as BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for treating blood cancers, and TEVIMBRA, an anti-PD-1 antibody immunotherapy for solid tumor and blood cancers. Additionally, the company has PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes, which is being evaluated as a monotherapy and in combinations for solid tumors.

The company's clinical-stage pipeline is robust, with multiple candidates in various stages of development. These include BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound; and Ociperlimab (BGB-A1217), a TIGIT inhibitor. Other notable candidates include Zanidatamab, a bispecific HER2-targeted antibody, and Surzebiclimab (BGB-A425), a TIM-3 inhibitor. The company is also exploring various preclinical programs, demonstrating its commitment to advancing cancer treatment options.

BeiGene has established strategic partnerships with several companies, including Ensem Therapeutics, Shandong Luye Pharmaceutical, and Amgen, to name a few. These collaborations enable the company to leverage its expertise and resources to accelerate the development of its pipeline. Founded in 2010, BeiGene is headquartered in Camana Bay, the Cayman Islands, and has a strong online presence at https://www.beigene.com.